Neratinib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 655 publications
Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer.
Journal: Cancer biology & medicine
Published: April 13, 2026
Novel benzimidazole-based thioamide derivatives as potential anticancer agents: synthesis, biological evaluation, and in silico studies.
Journal: Bioorganic chemistry
Published: February 21, 2026
Neratinib, a Clinical Drug Against Breast Cancer, Protects Against Vascular Inflammation and Atherosclerosis.
Journal: Circulation research
Published: January 09, 2026
Enhanced Payload Release Enables Disitamab Vedotin to Surpass Trastuzumab Emtansine and Retain Efficacy in Acquired Resistance to Clinical Anti-HER2 Therapies.
Journal: Pharmaceutics
Published: December 18, 2025
The ErbB-tyrosine kinase inhibitor, neratinib, has anti-inflammatory effects in multimorbidity by increasing macrophage efferocytosis via the upregulation of MerTK.
Journal: Journal of inflammation (London, England)
Published: December 17, 2025
FGFR2 is a Candidate Immune-Associated Marker of Diabetic Foot Ulcer That Promotes Keratinocyte Function by Activating the PI3K/Akt and MAPK Pathways.
Journal: Mediators of inflammation
Published: December 15, 2025
In-vitro and in-vivo CYP3A4 Variants: Neratinib metabolism and drug interaction risk.
Journal: Chemico-biological interactions
Published: December 08, 2025
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 13, 2025
Exploring tyrosine kinase inhibitors for HER2-positive breast cancer: comprehensive review on a complete pharmacology-molecular mechanisms, safety profiles, and insights from preclinical and clinical studies.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: November 12, 2025
Corrigendum to "Photosensitive smart hydrogel loaded Neratinib for NIR-triggered photodynamic treatment for improved chemotherapy in breast cancers- In vitro and In vivo analysis" [J. Pharm. Sci. 115 (1) (2026) 104016].
Journal: Journal of pharmaceutical sciences
Published: November 09, 2025
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity.
Journal: Journal of visualized experiments : JoVE
Published: November 03, 2025
A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease).
Journal: Therapeutic advances in medical oncology
Published: August 28, 2025
Last Updated: 04/28/2026